Abstract 740
Background
Poly ADP-ribose polymerase inhibitors (PARPIs) have received US and European regulatory approvals for the treatment of BRCA-associated ovarian cancer. The approval of PARPIs in rapid succession has resulted in a paradigm shift in the management of recurrent ovarian cancer.
Methods
2,116 ovarian cancer patients (pts) in advanced/metastatic (adv/met) lines of therapy from Jan 2016 to Oct 2018 in EU5 (France, Germany, Spain, Italy, UK) were identified within Oncology Dynamics, an IQVIA oncology-syndicated cross-sectional survey collecting anonymized patient-level data. Maintenance therapy was also investigated in 534 pts.
Results
Platinum-based regimens for the treatment of adv/met ovarian cancer pts decreased from 56% in 2017 to 50% by Oct 2018. In contrast, the use of PARPIs increased from 9% to 14%. A reduction in the administration of PARPIs was noted in all platinum-based regimens (▾15% and ▾13% in 2nd and 3rd+ lines adv/met) and in non-platinum chemotherapy (▾8% and ▾9% in 2nd and 3rd+ lines adv/met). However, in platinum-sensitive ovarian cancer pts, there has been an increase of PARPIs in 2nd and 3rd+ lines (given to 27% and 29% pts, respectively). The use in the 1st line adv/met setting has also increased by 3% (administered to 8% of pts). Prior to PARPIs, most of the pts were treated with platinum-based regimens (97%). As maintenance treatment, PARPIs have been most used in 2nd (26%) and 3rd+ line (22%) in platinum-sensitive adv/met ovarian cancer. 93% of adv/met ovarian cancer pts treated with PARPIs had an ECOG status of ≤ 1 and most suffered no comorbidities (50%). Peritoneum was the most common metastatic site (63%), followed by lymph nodes (38%). Nearly all pts had been tested for BRCA1/2 and 79% of them presented mutations. Progression was the most common reason for stopping treatment with PARPIs (72%); and anaemia, nausea, vomiting, neutropenia, and rash were the most common side effects on historic patient records.
Conclusions
PARPIs have certainly shown a meaningful impact on progression-free survival in pts with platinum-sensitive recurrent ovarian cancer, without any deleterious impact on the quality of life. The use of PARPIs is rising in the platinum-sensitive ovarian cancer population in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IQVIA.
Funding
IQVIA.
Disclosure
A. Martinez de Pinillos: Full / Part-time employment: IQVIA C. Anger: Full / Part-time employment: IQVIA L. Mendoza: Full / Part-time employment: IQVIA
Resources from the same session
3536 - Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis
Presenter: Mylin Torres
Session: Poster Display session 2
Resources:
Abstract
4022 - Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
3599 - Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
Presenter: Rachel Layman
Session: Poster Display session 2
Resources:
Abstract
901 - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumors
Presenter: Yung-Jue Bang
Session: Poster Display session 2
Resources:
Abstract
2777 - A Phase 2 study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL).
Presenter: Solmaz Sahebjam
Session: Poster Display session 2
Resources:
Abstract
3980 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Michelino De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
4024 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial
Presenter: Paul Cottu
Session: Poster Display session 2
Resources:
Abstract
2151 - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract
3994 - Safety and efficacy of Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study.
Presenter: Michele De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
1370 - Interim Results From CompLEEment-1 (A Phase 3b Study of Ribociclib and Letrozole as First-Line Therapy for Advanced Breast Cancer in an Expanded Population): Spanish cohort results
Presenter: Javier Salvador
Session: Poster Display session 2
Resources:
Abstract